I405V polymorphism of the cholesteryl ester transfer protein gene in young and very old individuals;Il polimorfismo I405V del gene della proteina di trasferimento degli esteri del colesterolo nei giovani e nei grandi vecchi

Annali Italiani di Medicina Interna

Volumn 20, Issue 1, 2005, Pages 45-50

  Lucchi, Tiziano ^a   Arosio, Beatrice ^a   Caloni, Marianna ^a   Ceconi, Ieda ^a   Calabresi, Carmen ^a   Scurati, Silvia ^a   Vergani, Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Lipoprotein metabolism; Longevity; Polymorphism i405V of the CETP gene

Indexed keywords

CARRIER PROTEIN; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; GLYCOPROTEIN;

ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 33644692881     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Istituto Nazionale di Statistica. Annuario statistico italiano 2003. Roma, 2004.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
3. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J 2004; 148 (Suppl): S14-S18.
4. Glueck CJ, Fallat RW, Millett F, Gartside P, Elston RC, Go RC. Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds. Metabolism 1975; 24: 1243-65.
5. Hayden MR, Clee SM, Brooks-Wilson A, Genest J Jr, Attie A, Kastelein JJ. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 2000; 11: 117-23.
6. Brewer HB Jr, Santamaria-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol 2003; 91: 3E-11E.
7. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-67.
8. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002; 43: 1997-2006.
9. Barter PJ, Rye KA. Molecular mechanism of reverse cholesterol transport. Curr Opin Lipidol 1996; 7: 82-7.
10. Inazu A, Koizumi J, Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol 2000; 11: 389-96.
11. Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 2002; 43: 1163-9.
12. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 2004; 43: 717-24.
13. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987; 327: 632-4.
14. Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997; 17: 560-8.
15. Tall AR, Dammerman M, Breslow JL. Disorders of lipoprotein metabolism. In: Chien KR, ed. Molecular basis of cardiovascular disease: a companion to Braunwald's heart disease. Philadelphia, PA: WB Saunders, 1999: 413-27.
16. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323: 1234-8.
17. Okumura K, Matsui H, Kamiya H, Saburi Y, Hayashi K, Hayakawa T. Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis 2002; 161: 425-31.
18. Knoblauch H, Bauerfeind A, Toliat MR, et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 2004; 13: 993-1004.
19. Boekholdt Matthijs S, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44: 1080-93.
20. Boekholdt Matthijs S, Kuivenhoven JA, Kees Hoving G, Wouter Jukema J, Kastelein JJP, van Tol A. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol 2004; 15: 393-8.
21. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290: 2030-40.
22. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
23. Miller SA, Dykes DD, Polesky HFA. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16: 1215.
24. Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest 1999; 29: 116-28.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
26. Smith SC Jr, Milani RV, Arnett DK, et al, for the American Heart Association. Atherosclerotic vascular disease conference. Writing Group II: risk factors. Circulation 2004; 109: 2613-6.
27. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997; 3: 744-9.
28. Barter PJ, Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 2001; 12: 377-82.
29. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406: 203-7.
30. De Grooth GJ, Zerba KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 2004; 43: 854-7.
31. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97: 2917-23.
32. Kuivenhoven JA, Wouter Ukema J, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.
33. Barter P, Kastelein J, Nunn A, Hobbs R, for the Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168: 195-211.
34. Ljungquist B, Berg S, Lanke J, McClearn GE, Pedersen NL. The effect of genetic factors for longevity: a comparison of identical and fraternal twins in the Swedish Twin Registry. J Gerontol A Biol Sci Med Sci 1998; 53: M441-M446.
35. Cooper RS. Gene-environment interactions and the etiology of common complex disease. Ann Intern Med 2003; 139: 437-40.
36. Scanu AM. Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 2003; 349: 2089-90.
37. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
38. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
39. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
40. Katzel LI, Goldberg AP. Dyslipoproteinemia. In: Hazzard WR, Blass JP, Halter JB, Ouslander JG, eds. Principles of geriatric medicine and gerontology. 5th ed. New York, NY: McGraw-Hill, 2003: 875-91.
41. Karlamangla AS, Singer BH, Reuben DB, Seeman TE. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functioning older adults: MacArthur studies of successful aging. J Am Geriatr Soc 2004; 52: 487-94.
42. Harris TB. Cholesterol and health in old age: risk factor or risk marker? J Am Geriatr Soc 2004; 52: 639-40.
43. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101: 1907-12.
44. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16.